GLP-1 Advisor

GLP-1 Advisor Evidence Update: September 2026 Do GLP-1 drugs cause nutrient deficiencies? GLP-1 receptor agonists and related incretin-based therapies can increase the risk of inadequate nutrition indirectly , mainly because appetite suppression, early satiety, food aversion, nausea, vomiting and major reductions in energy intake can make it harder to consume enough protein, vitamins, minerals, fiber and fluids. The important distinction is that GLP-1 medicines are not known to simply “drain” vitamins from the body . The nutritional problem is more often reduced intake and, in some people, gastrointestinal intolerance, restrictive eating or rapid weight loss. Recent 2026 evidence supports a targeted, individualized approach rather than a universal high-dose supplement stack. Core principle: The goal of GLP-1 nutrition is not maximum appetite ...

Authoritative Clinical Guide | Updated 2026 Short Answer Do GLP-1 drugs cause vitamin deficiencies? GLP-1 drugs like semaglutide and tirzepatide can increase the risk of nutrient deficiencies indirectly by reducing appetite and food intake. The most common deficiencies include vitamin B1, B12, vitamin D, iron, and magnesium. A structured nutrition and supplementation protocol can prevent these risks. Introduction GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most effective weight loss drugs ever developed. But there’s a growing clinical reality most patients—and many clinicians—are missing: GLP-1 therapy can quietly increase the risk of micronutrient deficiencies. Not because the drugs are “toxic”—but because they fundamentally change human physiology, appetite, and nutrient intake patterns. This guide breaks down: The real mechanisms (not hype) The highest-risk deficiencies (2026 data) A PubMed-aligned supplementation protocol ...